Deyaa Adib, MD, on Targeting HER2 in Solid Tumors With the TAC Platform

“We are looking at essentially all levels of [HER2] expression...and that could be a game changer. Based on the recent results we have seen in the breast cancer space, targeted therapies do have evidence of clinical activity in low and intermediate HER2 expression... and it is worth testing our targeted cell therapy in patients with low and intermediate HER2, to see if they benefit from this type of therapy.”

While therapies have targeted HER2 in solid tumors for decades now, most of those therapies have been focused exclusively on breast and gastric cancers. Triumvira Immunologics hopes to expand the indications for these therapies with the use of their novel T-cell Antigen Coupler (TAC) platform.

Deyaa Adib, MD, chief medical officer, Triumvira Immunologics, spoke with CGTLive about the company’s decision to target HER2 with the TAC platform in a phase 1/2 clinical trial (TACTIC-2, NCT04727151). Adib explained that HER2 is a well-recognized and well-established target for cell therapies. He also noted that despite this, there continues to be a significant unmet need for patients with HER2-expressing solid tumors outside the realm of breast cancer and gastric cancer.

Adib additionally described the details of the company’s on-going clinical trial, highlighting that it will expand to include patients with HER2-expressing solid tumors in any organs. He also emphasized that it will explore the efficacy of the therapy in patients with low and intermediate levels of HER2 expression. He noted the significance of this, mentioning that no previous therapies have been developed to target HER2 in patients with low and intermediate levels of expression.